Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s What Happened
by Renee Jackson · The Cerbat GemNanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $33.79, but opened at $30.54. Nanobiotix shares last traded at $30.49, with a volume of 3,760 shares trading hands.
Analysts Set New Price Targets
NBTX has been the subject of several analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Finally, Guggenheim increased their price objective on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $25.00.
Read Our Latest Research Report on Nanobiotix
Nanobiotix Stock Down 3.9%
The stock has a fifty day simple moving average of $30.52 and a 200-day simple moving average of $24.83.
Nanobiotix (NASDAQ:NBTX – Get Free Report) last released its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million during the quarter. Equities research analysts forecast that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Nanobiotix
Several hedge funds and other institutional investors have recently modified their holdings of NBTX. Royal Bank of Canada lifted its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the period. Optiver Holding B.V. bought a new position in shares of Nanobiotix during the 3rd quarter worth approximately $101,000. Marshall Wace LLP acquired a new stake in Nanobiotix during the 4th quarter valued at $220,000. Finally, Millennium Management LLC bought a new position in Nanobiotix in the 4th quarter valued at $390,000. Institutional investors own 38.81% of the company’s stock.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.